1932

Abstract

Specific psychological treatments have demonstrated efficacy and represent the first-line approaches recommended for anorexia nervosa, bulimia nervosa, and binge-eating disorder. Unfortunately, many patients, particularly those with anorexia nervosa, do not derive sufficient benefit from existing treatments, and better or alternative treatments for eating disorders are needed. Less progress has been made in developing pharmacologic options for eating disorders. No medications approved for anorexia nervosa exist, and only one each exists for bulimia nervosa and for binge-eating disorder; available data indicate that most patients fail to benefit from available medications. Longer and combined treatments have generally not enhanced outcomes. This review presents emerging findings from more complex and clinically relevant adaptive treatment designs, as they offer some clinical guidance and may serve as models for future enhanced treatment research.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-clinpsy-080822-043256
2024-07-12
2025-02-07
Loading full text...

Full text loading...

/deliver/fulltext/clinpsy/20/1/annurev-clinpsy-080822-043256.html?itemId=/content/journals/10.1146/annurev-clinpsy-080822-043256&mimeType=html&fmt=ahah

Literature Cited

  1. Agras WS, Bohon C. 2021.. Cognitive behavioral therapy for the eating disorders. . Annu. Rev. Clin. Psychol. 17::41738
    [Crossref] [Google Scholar]
  2. Agras WS, Brandt HA, Bulik CM, Dolan-Sewell R, Fairburn CG, et al. 2004.. Report of the National Institutes of Health workshop on overcoming barriers to treatment research in anorexia nervosa. . Int. J. Eat. Disord. 35::50921
    [Crossref] [Google Scholar]
  3. Agras WS, Rossiter EM, Arnow B, Schneider JA, Telch CF, et al. 1992.. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison. . Am. J. Psychiatry 149::8287
    [Crossref] [Google Scholar]
  4. Agras WS, Telch CF, Arnow B, Eldredge K, Detzer MJ, et al. 1995.. Does interpersonal therapy help patients with binge eating disorder who fail to respond to cognitive-behavioral therapy?. J. Consult. Clin. Psychol. 63::35660
    [Crossref] [Google Scholar]
  5. Agras WS, Telch CF, Arnow B, Eldredge K, Wilfley DE, et al. 1994.. Weight loss, cognitive-behavioral, and desipramine treatments in binge eating disorder: an additive design. . Behav. Ther. 25::22538
    [Crossref] [Google Scholar]
  6. Agras WS, Walsh BT, Fairburn CG, Wilson GT, Kraemer HC. 2000.. A multicenter comparison of cognitive-behavioral therapy and interpersonal psychotherapy for bulimia nervosa. . Arch. Gen. Psychiatry 57::45966
    [Crossref] [Google Scholar]
  7. Am. Psychiatr. Assoc. 2013.. Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA:: Am. Psychiatr. Assoc. , 5th ed..
    [Google Scholar]
  8. Añez LM, Paris M Jr., Bedregal LE, Davidson L, Grilo CM. 2005.. Application of cultural constructs in the care of first generation Latino clients in a community mental health setting. . J. Psychiatr. Pract. 11::22130
    [Crossref] [Google Scholar]
  9. Attia E, Kaplan AS, Walsh BT, Gershkovich M, Yilmaz Z, et al. 2011.. Olanzapine versus placebo for outpatients with anorexia nervosa. . Psychol. Med. 41::217782
    [Crossref] [Google Scholar]
  10. Attia E, Steinglass JE, Walsh BT, Wang Y, Wu P, et al. 2019.. Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial. . Am. J. Psychiatry 176::44956
    [Crossref] [Google Scholar]
  11. Bissada H, Tasca GA, Barber AM, Bradwejn J. 2008.. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. . Am. J. Psychiatry 165::128188
    [Crossref] [Google Scholar]
  12. Boswell RG, Potenza MN, Grilo CM. 2021.. The neurobiology of binge-eating disorder compared with obesity: implications for differential therapeutics. . Clin. Ther. 43::5069
    [Crossref] [Google Scholar]
  13. Brown TA, Keel PK. 2023.. Eating disorders in boys and men. . Annu. Rev. Clin. Psychol. 19::177205
    [Crossref] [Google Scholar]
  14. Brownell KD. 2000.. The LEARN Program for Weight Management. Dallas, TX:: Am. Health
    [Google Scholar]
  15. Burnette CB, Luzier JL, Weisenmuller CM, Boutte RL. 2022.. A systematic review of sociodemographic reporting and representation in eating disorder psychotherapy treatment trials in the United States. . Int. J. Eat. Disord. 55::42354
    [Crossref] [Google Scholar]
  16. Byrne S, Wade T, Hay P, Touyz S, Fairburn CG, et al. 2017.. A randomized controlled trial of three psychological treatments for anorexia nervosa. . Psychol. Med. 47::282333
    [Crossref] [Google Scholar]
  17. Citrome L. 2021.. Binge eating disorder: a psychiatrist's commentary on clinical considerations. . Clin. Ther. 43::716
    [Crossref] [Google Scholar]
  18. Claudino AM, de Oliveira IR, Appolinario JC, Cordas TA, Duchesne M, et al. 2007.. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. . J. Clin. Psychiatry 68::132432
    [Crossref] [Google Scholar]
  19. Clausen L, Semark BD, Helverskov J, Bulik CM, Peterson LV. 2023.. Pharmacotherapy in anorexia nervosa: a Danish nation-wide register-based study. . J. Psychosom. Res. 164::111077
    [Crossref] [Google Scholar]
  20. Coffino JA, Udo T, Grilo CM. 2019.. Rates of help-seeking in U.S. adults with lifetime DSM-5 eating disorders: prevalence across diagnoses and sex and ethnic/racial differences. . Mayo Clin. Proc. 94::141526
    [Crossref] [Google Scholar]
  21. Comer JS, Barlow DH. 2014.. The occasional case against broad dissemination and implementation: retaining a role for specialty care in the delivery of psychological treatments. . Am. Psychol. 69::118
    [Crossref] [Google Scholar]
  22. Cowley MA, Smart JL, Rubinstein M, Cerdán MG, Diano S, et al. 2001.. Leptin activates anorexigenic POMC neurons through neural network in the arcuate nucleus. . Nature 411::48084
    [Crossref] [Google Scholar]
  23. Deloitte. 2020.. The social and economic cost of eating disorders in the United States of America: a report for the Strategic Training Initiative for the Prevention of Eating Disorders and the Academy for Eating Disorders. Rep. , Deloitte, New York:. https://www.hsph.harvard.edu/striped/report-economic-costs-of-eating-disorders
    [Google Scholar]
  24. DPP Res. Group. 2002.. The Diabetes Prevention Program (DPP): description of lifestyle intervention. . Diabetes Care 25::216571
    [Crossref] [Google Scholar]
  25. Eisler I, Lock J, le Grange D. 2010.. Family-based treatments for adolescents with anorexia nervosa: single-family and multifamily approaches. . In The Treatment of Eating Disorders, ed. CM Grilo, JE Mitchell , pp. 15074. New York:: Guilford
    [Google Scholar]
  26. Eisler I, Simic M, Hodsoll J, Asen E, Berelowitz M, et al. 2016.. A pragmatic randomized multi-centre trial of multifamily and single-family therapy for adolescent anorexia nervosa. . BMC Psychiatry 16::422
    [Crossref] [Google Scholar]
  27. Eysenck HJ. 1978.. An exercise in mega-silliness. . Am. Psychol. 33::51719
    [Crossref] [Google Scholar]
  28. Fairburn CG, Bailey-Straebler S, Basden S, Doll H, Jones R, et al. 2015.. A transdiagnostic comparison of enhanced cognitive-behavioral therapy (CBT-E) and interpersonal psychotherapy in the treatment of eating disorders. . Behav. Res. Ther. 70::6471
    [Crossref] [Google Scholar]
  29. Fairburn CG, Cooper Z, Doll HA, O'Connor ME, Bohn K, et al. 2009.. Transdiagnostic cognitive-behavioral therapy for patients with eating disorders: a two-site trial with 60-week follow-up. . Am. J. Psychiatry 166::31119
    [Crossref] [Google Scholar]
  30. Fairburn CG, Cooper Z, Doll HA, O'Connor ME, Palmer RL, Dalle Grave R. 2013.. Enhanced cognitive behaviour therapy for adults with anorexia nervosa: a UK–Italy study. . Behav. Res. Ther. 51::R28
    [Crossref] [Google Scholar]
  31. Fairburn CG, Cooper Z, Shafran R. 2003.. Cognitive behaviour therapy for eating disorders: a “transdiagnostic” theory and treatment. . Behav. Res. Ther. 41::50928
    [Crossref] [Google Scholar]
  32. Fairburn CG, Jones R, Peveler RC, Carr SJ, Solomon RA, et al. 1991.. Three psychological treatments for BN: a comparative trial. . Arch. Gen. Psychiatry 48::46369
    [Crossref] [Google Scholar]
  33. Fairburn CG, Jones R, Peveler RC, Hope RA, O'Connor M. 1993.. Longer-term effects of interpersonal psychotherapy, behavior therapy, and cognitive-behavior therapy. . Arch. Gen. Psychiatry 50::41028
    [Crossref] [Google Scholar]
  34. FBNCSG (Fluoxetine Bulim. Nerv. Collab. Study Group). 1992.. Fluoxetine in the treatment of bulimia nervosa: a multicenter placebo-controlled double-blind trial. . Arch. Gen. Psychiatry 49::13947
    [Crossref] [Google Scholar]
  35. Forrest LN, Jacobucci RC, Grilo CM. 2022.. Empirically determined severity levels for binge-eating disorder outperform existing severity classification schemes. . Psychol. Med. 52::68595
    [Crossref] [Google Scholar]
  36. Gasior M, Hudson JI, Quintero J, Ferreira-Cornwell MC, Radewonuk J, McElroy SL. 2017.. A phase 3, multi-center, open-label, 12-month extension safety and tolerability trial of lisdexamfetamine dimesylate in adults with binge eating disorder. . J. Clin. Psychopharmacol. 37::31522
    [Crossref] [Google Scholar]
  37. Golay A, Laurent-Jaccard A, Habicht F, Gachoud JP, Chabloz M, et al. 2005.. Effect of orlistat in obese patients with binge eating disorder. . Obes. Res. 13::17018
    [Crossref] [Google Scholar]
  38. Goldbloom DS, Olmsted M, Davis R, Clewes J, Heinmaa M, et al. 1997.. A randomized controlled trial of fluoxetine and cognitive behavioral therapy for bulimia nervosa: short-term outcome. . Behav. Res. Ther. 35::80311
    [Crossref] [Google Scholar]
  39. Goldstein DJ, Wilson MG, Ascroft RC, Al-Banna M. 1999.. Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. . Int. J. Eat. Disord. 25::1927
    [Crossref] [Google Scholar]
  40. Goldstein DJ, Wilson MG, Thompson VL, Potvin JH, Rampey AH. 1995.. Long-term fluoxetine treatment of bulimia nervosa. . Br. J. Psychiatry 166::66066
    [Crossref] [Google Scholar]
  41. Grilo CM. 2013.. Why no cognitive body image feature such as overvaluation of shape/weight in the binge eating disorder diagnosis?. Int. J. Eat. Disord. 46::20811
    [Crossref] [Google Scholar]
  42. Grilo CM. 2017.. Psychological and behavioral treatments for binge-eating disorder. . J. Clin. Psychiatry 78:(Suppl. 1):2024
    [Crossref] [Google Scholar]
  43. Grilo CM, Crosby RD, Wilson GT, Masheb RM. 2012a.. 12-month follow-up of fluoxetine and cognitive behavioral therapy for binge eating disorder. . J. Consult. Clin. Psychol. 80::110813
    [Crossref] [Google Scholar]
  44. Grilo CM, Juarascio A. 2023.. Binge-eating disorder interventions: review, current status, and implications. . Curr. Obes. Rep. 12::40616
    [Crossref] [Google Scholar]
  45. Grilo CM, Lydecker JA, Fineberg SK, Moreno JO, Ivezaj V, Gueorguieva R. 2022.. Naltrexone-bupropion combination medication and behavior therapy, alone and combined, for binge-eating disorder: randomized double-blind placebo-controlled trial. . Am. J. Psychiatry 179::92737
    [Crossref] [Google Scholar]
  46. Grilo CM, Lydecker JA, Gueorguieva R. 2023a.. Naltrexone plus bupropion combination maintenance treatment for binge eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial. . Psychol. Med. 53::777584
    [Crossref] [Google Scholar]
  47. Grilo CM, Lydecker JA, Gueorguieva R. 2023b.. Cognitive-behavioral therapy for binge-eating disorder for non-responders to initial acute treatments: randomized controlled trial. . Int. J. Eat. Disord. 56::154453
    [Crossref] [Google Scholar]
  48. Grilo CM, Lydecker JA, Jastreboff AM, Pittman B, McKee SA. 2023c.. Naltrexone/bupropion for binge-eating disorder: a randomized, double-blind, placebo-controlled trial. . Obesity 31::276273
    [Crossref] [Google Scholar]
  49. Grilo CM, Masheb RM. 2005.. A randomized controlled comparison of guided self-help cognitive behavioral therapy and behavioral weight loss for binge eating disorder. . Behav. Res. Ther. 43::150925
    [Crossref] [Google Scholar]
  50. Grilo CM, Masheb RM, Crosby R. 2012b.. Predictors and moderators of response to cognitive behavioral therapy and medication for the treatment of binge eating disorder. . J. Consult. Clin. Psychol. 80::897906
    [Crossref] [Google Scholar]
  51. Grilo CM, Masheb RM, Salant SL. 2005a.. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. . Biol. Psychiatry 57::1193201
    [Crossref] [Google Scholar]
  52. Grilo CM, Masheb RM, White MA, Gueorguieva R, Barnes RD, et al. 2014.. Treatment of binge eating in racially and ethnically diverse obese patients in primary care: randomized placebo-controlled clinical trial of self-help and medication. . Behav. Res. Ther. 58::19
    [Crossref] [Google Scholar]
  53. Grilo CM, Masheb RM, Wilson GT. 2005b.. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. . Biol. Psychiatry 57::3019
    [Crossref] [Google Scholar]
  54. Grilo CM, Masheb RM, Wilson GT. 2006.. Rapid response to treatment for binge eating disorder. . J. Consult. Clin. Psychol. 74::60213
    [Crossref] [Google Scholar]
  55. Grilo CM, Masheb RM, Wilson GT, Gueorguieva R, White MA. 2011.. Cognitive-behavioral therapy, behavioral weight loss, and sequential treatment for obese patients with binge-eating disorder: a randomized controlled trial. . J. Consult. Clin. Psychol. 79::67585
    [Crossref] [Google Scholar]
  56. Grilo CM, Thompson-Brenner H, Shingleton RM, Thompson DR, Franko DL. 2021.. Clinical moderators and predictors of cognitive-behavioral therapy by guided self-help versus therapist-led for binge-eating disorders: analysis of aggregated clinical trials. . Int. J. Eat. Disord. 54::187580
    [Crossref] [Google Scholar]
  57. Grilo CM, White MA. 2013.. Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as. . Behav. Res. Ther. 51::16775
    [Crossref] [Google Scholar]
  58. Grilo CM, White MA, Masheb RM, Ivezaj V, Morgan PT, Gueorguieva R. 2020.. Randomized controlled trial testing the effectiveness of adaptive “SMART” stepped-care treatment for adults with binge-eating disorder comorbid with obesity. . Am. Psychol. 75::20418
    [Crossref] [Google Scholar]
  59. Grilo CM, White MA, Wilson GT, Gueorguieva R, Masheb RM. 2012c.. Rapid response predicts 12-month post-treatment outcomes in binge-eating disorder: theoretical and clinical implications. . Psychol. Med. 42::80717
    [Crossref] [Google Scholar]
  60. Halmi KA, Eckert E, LaDu T, Cohen J. 1986.. Anorexia nervosa: treatment efficacy of cyproheptadine and amitriptyline. . Arch. Gen. Psychiatry 43::17781
    [Crossref] [Google Scholar]
  61. Hilbert A, Bishop M, Stein R, Wilfley DE. 2012.. Long-term efficacy of psychological treatments for binge eating disorder. . Br. J. Psychiatry 200::23237
    [Crossref] [Google Scholar]
  62. Hilbert A, Hoek HW, Schmidt R. 2017.. Evidence-based clinical guidelines for eating disorders: international comparison. . Curr. Opin. Psychiatry 30::42337
    [Crossref] [Google Scholar]
  63. Hilbert A, Petroff D, Herpertz S, Pietrowsky R, Tuschen-Caffier B, et al. 2019.. Meta-analysis of the efficacy of psychological and medical treatments for binge-eating disorder. . J. Consult. Clin. Psychol. 87::91105
    [Crossref] [Google Scholar]
  64. Himmerich H, Lewis YD, Conti C, Mutwalli H, Karwautz A, et al. 2023.. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders. . World J. Biol. Psychiatry 24::643706
    [Crossref] [Google Scholar]
  65. Hoopes SP, Reimherr FW, Hedges DW, Rosenthal NR, Kamin M, et al. 2003.. Treatment of bulimia nervosa with topiramate in a randomized double-blind placebo-controlled trial, part 1: improvement in binge and purge measures. . J. Clin. Psychiatry 64::133541
    [Crossref] [Google Scholar]
  66. Horne RL, Ferguson JM, Pope HG Jr., Hudson JI, Lineberry CG, et al. 1988.. Treatment of bulimia with bupropion: a multicenter controlled trial. . J. Clin. Psychiatry 49::26266
    [Google Scholar]
  67. Hudson JI, Hiripi E, Pope HG Jr., Kessler RC. 2007.. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. . Biol. Psychiatry 61::34858
    [Crossref] [Google Scholar]
  68. Hudson JI, McElroy SL, Ferreira-Cornwell C, Radewonuk J, Gasior M. 2017.. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial. . JAMA Psychiatry 74::90310
    [Crossref] [Google Scholar]
  69. Hughes EK, Sawyer SM, Accurso EC, Singh S, le Grange D. 2019.. Predictors of early response in cojoint and separated models of family-based treatments for adolescent anorexia nervosa. . Eur. Eat. Disord. Rev. 27::28394
    [Crossref] [Google Scholar]
  70. Jacobi C, Dahme B, Dittmann R. 2002.. Cognitive-behavioural, fluoxetine and combined treatment for bulimia nervosa: short- and long-term results. . Eur. Eat. Disord. Rev. 10::17998
    [Crossref] [Google Scholar]
  71. Kaidesoja M, Cooper Z, Fordham B. 2023.. Cognitive behavioral therapy for eating disorders: a map of the systematic review evidence base. . Int. J. Eat. Disord. 56::295313
    [Crossref] [Google Scholar]
  72. Kaye WH. 2008.. Neurobiology of anorexia and bulimia nervosa. . Physiol. Behav. 94::12135
    [Crossref] [Google Scholar]
  73. Kaye WH, Bulik CM. 2021.. Treatment of patients with anorexia nervosa in the US—a crisis in care. . JAMA Psychiatry 78::59192
    [Crossref] [Google Scholar]
  74. Kazdin AE, Fitzsimmons-Craft EE, Wilfley DE. 2017.. Addressing critical gaps in the treatment of eating disorders. . Int. J. Eat. Disord. 50::17087
    [Crossref] [Google Scholar]
  75. Keski-Rahkonen A, Mustelin L. 2016.. Epidemiology of eating disorders in Europe: prevalence, incidence, comorbidity, course, consequences, and risk factors. . Curr. Opin. Psychiatry 29::34045
    [Crossref] [Google Scholar]
  76. Kessler RC, Berglund PA, Chiu WT, Deitz AC, Hudson JI, et al. 2013.. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. . Biol. Psychiatry 73::90414
    [Crossref] [Google Scholar]
  77. le Grange D, Hughes EK, Court A, Yeo M, Crosby RD, Sawyer SM. 2016.. Randomized clinical trial of parent-focused treatment and family-based treatment for adolescent anorexia nervosa. . J. Am. Acad. Child Adolesc. Psychiatry 55::68392
    [Crossref] [Google Scholar]
  78. Linardon J, Brennan L, de la Piedad Garcia X. 2016.. Rapid response to eating disorder treatment: a systematic review and meta-analysis. . Int. J. Eat. Disord. 49::90519
    [Crossref] [Google Scholar]
  79. Linardon J, de la Piedad Garcia X, Brennan L. 2017.. Predictors, moderators, and mediators of treatment outcome following manualised cognitive-behavioural therapy for eating disorders: a systematic review. . Eur. Eat. Disord. Rev. 25::312
    [Crossref] [Google Scholar]
  80. Lock J, Brandt H, Woodside B, Agras WS, Halmi K, et al. 2012.. Challenges in conducting a multi-site randomized clinical trial comparing treatments for adolescent anorexia nervosa. . Int. J. Eat. Disord. 45::20213
    [Crossref] [Google Scholar]
  81. Lock J, Kraemer HC, Jo B, Couturier J. 2019.. When meta-analyses get it wrong: response to “Treatment outcomes for anorexia nervosa: a systematic review and meta-analysis of randomized controlled trials. .” Psychol. Med. 49::60798
    [Crossref] [Google Scholar]
  82. Lock J, le Grange D, Agras WS, Moye A, Bryson SW, Jo B. 2010.. Randomized clinical trial comparing family-based treatment with adolescent-focused individual therapy for adolescents with anorexia nervosa. . Arch. Gen. Psychiatry 67::102532
    [Crossref] [Google Scholar]
  83. Lydecker JA, Grilo CM. 2022.. Psychiatric comorbidity as a predictor and moderator of binge-eating disorder treatment outcomes: an analysis of aggregated randomized controlled trials. . Psychol. Med. 52::408593
    [Crossref] [Google Scholar]
  84. Lydecker JA, Gueorguieva R, Masheb RM, White MA, Grilo CM. 2019.. Examining race as a predictor and moderator of treatment outcomes for binge-eating disorder: analysis of aggregated randomized controlled trials. . J. Consult. Clin. Psychol. 87::53040
    [Crossref] [Google Scholar]
  85. Lydecker JA, Gueorguieva R, Masheb RM, White MA, Grilo CM. 2020.. Examining sex as a predictor and moderator of treatment outcomes for binge-eating disorder: analysis of aggregated randomized controlled trials. . Int. J. Eat. Disord. 53::2030
    [Crossref] [Google Scholar]
  86. Lynch FL, Striegel-Moore RH, Dickerson JF, Perrin N, Debar L, et al. 2010.. Cost-effectiveness of guided self-help treatments for recurrent binge eating. . J. Consult. Clin. Psychol. 78::32233
    [Crossref] [Google Scholar]
  87. Marques L, Alegria M, Becker AE, Chen CN, Fang A, et al. 2011.. Comparative prevalence, correlates of impairment, and service utilization for eating disorders across US ethnic groups: Implications for reducing ethnic disparities in health care access for eating disorders. . Int. J. Eat. Disord. 44::41220
    [Crossref] [Google Scholar]
  88. McElroy SL. 2017.. Pharmacologic treatments for binge-eating disorder. . J. Clin. Psychiatry 78:(Suppl. 1):1419
    [Crossref] [Google Scholar]
  89. McElroy SL, Arnold LM, Shapira NA, Keck PE, Rosenthal NR, et al. 2003.. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized placebo-controlled trial. . Am. J. Psychiatry 160::25561
    [Crossref] [Google Scholar]
  90. McElroy SL, Guerdjikova AI, Mori N, Romo-Nava F. 2019.. Progress in developing pharmacologic agents to treat bulimia nervosa. . CNS Drugs 33::3146
    [Crossref] [Google Scholar]
  91. McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, et al. 2007.. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. . Biol. Psychiatry 61::103948
    [Crossref] [Google Scholar]
  92. McElroy SL, Hudson JI, Ferreira-Cornwell M, Radewonuk J, Whitaker T, Gasior M. 2016.. Lisdexamfetamine dimesylate for adults with moderate to severe binge-eating disorder: results of two pivotal phase 3 randomized controlled trials. . Neuropsychopharmacology 41::125160
    [Crossref] [Google Scholar]
  93. McElroy SL, Hudson JI, Gasior M, Herman BK, Radewonuk J, et al. 2017.. Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized double-blind placebo-controlled trials in adults with binge eating disorder. . Int. J. Eat. Disord. 50::88492
    [Crossref] [Google Scholar]
  94. McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, et al. 2015.. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. . JAMA Psychiatry 72::23546
    [Crossref] [Google Scholar]
  95. McElroy SL, Shapira NA, Arnold LM, Keck PE, Rosenthal NR, et al. 2004.. Topiramate in the long-term treatment of binge eating disorder associated with obesity. . J. Clin. Psychiatry 65::146369
    [Crossref] [Google Scholar]
  96. Mehler PS, Krantz MJ, Sachs KV. 2015.. Treatments of medical complications of anorexia nervosa and bulimia nervosa. . J. Eat. Disord. 3::15
    [Crossref] [Google Scholar]
  97. Mitchell JE, Agras S, Crow S, Halmi K, Fairburn CG, et al. 2011.. Stepped care and cognitive-behavioural therapy for bulimia nervosa: randomised trial. . Br. J. Psychiatry 198::39197
    [Crossref] [Google Scholar]
  98. Mitchell JE, Fletcher L, Hanson K, Mussell MP, Seim H, et al. 2001.. The relative efficacy of fluoxetine and manual-based self-help in the treatment of outpatients with bulimia nervosa. . J. Clin. Psychopharmacol. 21::298304
    [Crossref] [Google Scholar]
  99. Mitchell JE, Pyle RL, Eckert ED, Hatsukami D, Pomeroy C, Zimmerman R. 1990.. A comparison study of antidepressants and structured intensive group psychotherapy in the treatment of bulimia nervosa. . Arch. Gen. Psychiatry 47::14957
    [Crossref] [Google Scholar]
  100. Monteleone AM, Pellegrino F, Croatto G, Carfagno M, Hilbert A, et al. 2022.. Treatment of eating disorder: a systematic meta-review of meta-analyses and network meta-analyses. . Neurosci. Biobehav. Rev. 142::104857
    [Crossref] [Google Scholar]
  101. Mulkens S, Waller G. 2021.. New developments in cognitive-behavioural therapy for eating disorders (CBT-ED). . Curr. Opin. Psychiatry 34::57683
    [Crossref] [Google Scholar]
  102. Muratore AF, Attia E. 2021.. Current therapeutic approaches to anorexia nervosa: state of the art. . Clin. Ther. 43::8594
    [Crossref] [Google Scholar]
  103. Murray SB, Quintana DS, Loeb KL, Griffiths S, le Grange D. 2019.. Treatment outcomes for anorexia nervosa: a systematic review and meta-analysis of randomized controlled trials. . Psychol. Med. 49::53544
    [Crossref] [Google Scholar]
  104. Nelson LD, Simmons J, Simonsohn U. 2018.. Psychology's renaissance. . Annu. Rev. Psychol. 69::51134
    [Crossref] [Google Scholar]
  105. NICE (Natl. Inst. Health Clin. Excel.). 2017.. Eating disorders: recognition and treatment. Guidel. NG69 , NICE, Washington, DC:
    [Google Scholar]
  106. Nickel C, Tritt K, Muehlbacher M, Pedrosa F, Mitterlehner FO, et al. 2005.. Topiramate treatment in bulimia nervosa patients: a randomized double-blind placebo-controlled trial. . Int. J. Eat. Disord. 38::295300
    [Crossref] [Google Scholar]
  107. NIH (Natl. Inst. Health). 2000.. NIH guidelines on the inclusion of women and minorities as subjects in clinical research. Treat. Guidel., NIH, Bethesda, MD:. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-048.html
    [Google Scholar]
  108. Poulsen S, Lunn S, Daniel SI, Folke S, Mathiesen BB, et al. 2014.. A randomized controlled trial of psychanalytic psychotherapy or cognitive-behavioral therapy for bulimia nervosa. . Am. J. Psychiatry 171::10916
    [Crossref] [Google Scholar]
  109. Reas DL, Grilo CM. 2008.. Review and meta-analysis of pharmacotherapy for binge-eating disorder. . Obesity 16::202438
    [Crossref] [Google Scholar]
  110. Reas DL, Grilo CM. 2015.. Pharmacological treatment of binge eating disorder: update review and synthesis. . Exp. Opin. Pharmacother. 16::146378
    [Crossref] [Google Scholar]
  111. Reas DL, Grilo CM. 2021.. Psychotherapy and medications for eating disorders: better together?. Clin. Ther. 43::1739
    [Crossref] [Google Scholar]
  112. Ricca V, Castellini G, Lo Sauro C, Rotella CM, Faravelli C. 2009.. Zonisamide combined with cognitive behavioral therapy in binge eating disorder: a one-year follow-up study. . Psychiatry 6::2328
    [Google Scholar]
  113. Ricca V, Mannucci E, Mezzani B, Moretti S, Di Bernardo M, et al. 2001.. Fluoxetine and fluvoxamine combined with individual cognitive-behavioral therapy in binge eating disorder: a one-year follow-up study. . Psychother. Psychosom. 70::298306
    [Crossref] [Google Scholar]
  114. Romano SJ, Halmi KA, Sarker NP, Koke SC, Lee JS. 2002.. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. . Am. J. Psychiatry 159::96102
    [Crossref] [Google Scholar]
  115. Santomauro DF, Melen S, Mitchison D, Vos T, Whiteford H, Ferrari A. 2021.. The hidden burden of eating disorder: an extension of estimates from the Global Burden of Disease study 2019. . Lancet Psychiatry 8::32028
    [Crossref] [Google Scholar]
  116. Schmidt U, Magill N, Renwick B, Keyes A, Kenyon M, et al. 2015.. The Maudsley Outpatient Study of Treatments for Anorexia Nervosa and Related Conditions (MOSAIC). Comparison of the Maudsley Model of Anorexia Nervosa Treatment for Adults (MANTRA) with specialist supportive clinical management (SSCM) in outpatients with broadly defined anorexia nervosa: a randomized controlled trial. . J. Consult. Clin. Psychol. 83::796807
    [Crossref] [Google Scholar]
  117. Schmidt U, Ryan E, Bartholdy S, Renwick B, Keyes A, et al. 2016.. Two-year follow-up of the MOSAIC trial: a multi-center randomized controlled trial comparing two psychological treatments in adult outpatients with broadly defined anorexia nervosa. . Int. J. Eat. Disord. 49::793800
    [Crossref] [Google Scholar]
  118. Shingleton RM, Thompson-Brenner H, Thompson DR, Pratt EM, Franko DL. 2015.. Gender differences in clinical trials of binge eating disorder: an analysis of aggregated data. . J. Consult. Clin. Psychol. 83::38286
    [Crossref] [Google Scholar]
  119. Smith ML, Glass GV. 1977.. Meta-analysis of psychotherapy outcome studies. . Am. Psychol. 32::75260
    [Crossref] [Google Scholar]
  120. Stein DJ, Szatmari P, Gaebel W, Berk M, Vieta E, et al. 2020.. Mental, behavioral and neurodevelopmental disorders in the ICD-11: an international perspective on key changes and controversies. . BMC Med. 18::21
    [Crossref] [Google Scholar]
  121. Streatfeild J, Hickson J, Austin SB, Hutcheson R, Kandel JS, et al. 2021.. Social and economic cost of eating disorders in the United States: evidence to inform practice. . Int. J. Eat. Disord. 54::85168
    [Crossref] [Google Scholar]
  122. Sysko R, Sha N, Wang Y, Duan N, Walsh BT. 2010.. Early response to antidepressant treatment in bulimia nervosa. . Psychol. Med. 40::9991005
    [Crossref] [Google Scholar]
  123. Thompson-Brenner H, Franko DL, Thompson DR, Grilo CM, Boisseau CL, et al. 2013.. Race/ethnicity, education, and treatment parameters as moderators and predictors of outcome in binge eating disorder. . J. Consult. Clin. Psychol. 81::71021
    [Crossref] [Google Scholar]
  124. Turner H, Marshall E, Stopa L, Waller G. 2015.. Cognitive-behavioural therapy for outpatients with eating disorders: effectiveness for a transdiagnostic group in routine clinical setting. . Behav. Res. Ther. 68::7075
    [Crossref] [Google Scholar]
  125. Udo T, Bitley S, Grilo CM. 2019.. Suicide attempts in US adults with lifetime DSM-5 eating disorders. . BMC Med. 17::120
    [Crossref] [Google Scholar]
  126. Udo T, Grilo CM. 2018.. Prevalence and correlates of DSM-5-defined eating disorders in a nationally representative sample of US adults. . Biol. Psychiatry 84::34554
    [Crossref] [Google Scholar]
  127. Udo T, Grilo CM. 2019.. Psychiatric and medical correlates of DSM-5 eating disorders in a nationally representative sample of adults in the US. . Int. J. Eat. Disord. 52::4250
    [Crossref] [Google Scholar]
  128. van den Berg E, Houtzager L, de Vos J, Daemen I, Katsaragaki G, et al. 2019.. Meta-analysis on the efficacy of psychological treatments for anorexia nervosa. . Eur. Eat. Disord. Rev. 27::33151
    [Crossref] [Google Scholar]
  129. van den Berg E, Schlochtermeier D, Koenders J, de Mooij L, Goudriaan A, et al. 2020.. Implementing cognitive therapy-enhanced in a routine inpatient and outpatient setting: comparing effectiveness and treatment costs in two consecutive cohorts. . Int. J. Eat. Disord. 53::46171
    [Crossref] [Google Scholar]
  130. van Eeden AE, van Hoeken D, Hoek HW. 2021.. Incidence, prevalence and mortality of anorexia nervosa and bulimia nervosa. . Curr. Opin. Psychiatry 34::51524
    [Crossref] [Google Scholar]
  131. Wade TD, Shafran R, Cooper Z. 2023.. Developing a protocol to address co-occurring mental Health conditions in the treatment of eating disorders. . Int. J. Eat. Disord. In press. https://doi.org/10.1002/eat.24008
    [Google Scholar]
  132. Walsh BT. 2019.. Diagnostic categories for eating disorders: current status and what lies ahead. . Psychiatr. Clin. N. Am. 42::110
    [Crossref] [Google Scholar]
  133. Walsh BT, Agras WS, Devlin MJ, Fairburn CG, Wilson GT, et al. 2000.. Fluoxetine for bulimia nervosa following poor response to psychotherapy. . Am. J. Psychiatry 157::133234
    [Crossref] [Google Scholar]
  134. Walsh BT, Fairburn CG, Mickley D, Sysko R, Parides MK. 2004.. Treatment of bulimia nervosa in a primary care setting. . Am. J. Psychiatry 161::55661
    [Crossref] [Google Scholar]
  135. Walsh BT, Hadigan CM, Devlin MJ, Gladis M, Roose SP. 1991.. Long-term outcome of antidepressant treatment for bulimia nervosa. . Am. J. Psychiatry 148::120612
    [Crossref] [Google Scholar]
  136. Walsh BT, Hagan KE, Lockwood C. 2023.. A systematic review comparing atypical anorexia nervosa and anorexia nervosa. . Int. J. Eat. Disord. 56::798820
    [Crossref] [Google Scholar]
  137. Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, et al. 2006.. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. . J. Am. Med. Assoc. 295::260512
    [Google Scholar]
  138. Walsh BT, Wilson GT, Loeb KL, Devlin MJ, Pike KM, et al. 1997.. Medication and psychotherapy in the treatment of bulimia nervosa. . Am. J. Psychiatry 154::52331
    [Crossref] [Google Scholar]
  139. Walsh BT, Xu T, Wang Y, Attia E, Kaplan AS. 2021.. Time course of relapse following acute treatment for anorexia nervosa. . Am. J. Psychiatry 178::84853
    [Crossref] [Google Scholar]
  140. Weisz JR, Venturo-Conerly KE, Fitzpatrick OM, Frederick JA, Ng MY. 2023.. What four decades of meta-analysis have taught us about youth psychotherapy and the science of research synthesis. . Annu. Rev. Clin. Psychol. 19::79105
    [Crossref] [Google Scholar]
  141. WHO (World Health Organ.). 2019.. International Statistical Classification of Diseases and Related Health Problems. Geneva:: WHO. 11th rev. https://icd.who.int
    [Google Scholar]
  142. Wilfley DE, Welch RR, Stein RI, Spurrell EB, Cohen LR, et al. 2002.. A randomized comparison of group cognitive-behavioral therapy and group interpersonal psychotherapy for the treatment of overweight individuals with binge-eating disorder. . Arch. Gen. Psychiatry 59::71321
    [Crossref] [Google Scholar]
  143. Wilson GT, Grilo CM, Vitousek KM. 2007.. Psychological treatment of eating disorders. . Am. Psychol. 62::199216
    [Crossref] [Google Scholar]
  144. Wilson GT, Wilfley DE, Agras WS, Bryson SW. 2010.. Psychological treatments of binge eating disorder. . Arch. Gen. Psychiatry 67::94101
    [Crossref] [Google Scholar]
  145. Wilson GT, Zandberg LJ. 2012.. Cognitive-behavioral guided self-help for eating disorders: effectiveness and scalability. . Clin. Psychol. Rev. 32::34357
    [Crossref] [Google Scholar]
  146. Wright F, Malone SK, Wong A, Melkus GD, Dickson VV. 2022.. Addressing challenges in recruiting diverse populations for research. . Nurs. Res. 71::21826
    [Crossref] [Google Scholar]
  147. Zerwas S, Larsen JT, Petersen L, Thornton LM, Mortensen PB, Bulik CM. 2015.. The incidence of eating disorders in a Danish register study: associations with suicide risk and mortality. . J. Psychiatr. Res. 65::1622
    [Crossref] [Google Scholar]
  148. Zipfel S, Wild B, Grob G, Friederich HC, Teufel M, et al. 2014.. Focal psychodynamic therapy, cognitive behaviour therapy, and optimized treatments as usual in outpatients with anorexia nervosa (ANTOP study): randomized controlled trial. . Lancet 383::12737
    [Crossref] [Google Scholar]
/content/journals/10.1146/annurev-clinpsy-080822-043256
Loading
  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error